Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?
暂无分享,去创建一个
[1] Ahmed M. Gad,et al. Linear Mixed Models for Longitudinal Data with Nonrandom Dropouts , 2006, Journal of Data Science.
[2] A. Nederveen,et al. Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned , 2014, Journal of Inherited Metabolic Disease.
[3] D. Zahrieh,et al. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up. , 2014, Blood cells, molecules & diseases.
[4] D. Rosenthal,et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat , 2014, Skeletal Radiology.
[5] C. Hollak,et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. , 2013, Blood cells, molecules & diseases.
[6] F. Sedel,et al. The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients , 2012, Orphanet Journal of Rare Diseases.
[7] D Gianola,et al. Technical note: an R package for fitting generalized linear mixed models in animal breeding. , 2010, Journal of animal science.
[8] G. Grabowski. Phenotype, diagnosis, and treatment of Gaucher's disease , 2008, The Lancet.
[9] C. Hollak,et al. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy , 2008, Haematologica.
[10] A. Haims,et al. Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. , 2008, AJR. American journal of roentgenology.
[11] P. Kaplan,et al. Prevalence of type 1 Gaucher disease in the United States. , 2008, Archives of internal medicine.
[12] J. Goldblatt,et al. Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. , 2007, AJR. American journal of roentgenology.
[13] P. Alfonso,et al. S-MRI score: A simple method for assessing bone marrow involvement in Gaucher disease. , 2007, European journal of radiology.
[14] R. Brady,et al. Enzyme replacement and gene therapy for Gaucher's disease , 1996, Lipids.
[15] K. Lutsky,et al. Orthopaedic manifestations of Gaucher disease. , 2007, Bulletin of the NYU hospital for joint diseases.
[16] P. Meikle,et al. Epidemiology of lysosomal storage diseases: an overview , 2006 .
[17] K. Sims,et al. Quality of life assessment in adults with type 1 Gaucher disease , 1999, Quality of Life Research.
[18] G. D. den Heeten,et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging--initial experience. , 2003, Radiology.
[19] B. Bembi,et al. Response of Gaucher bone disease to enzyme replacement therapy. , 2002, The British journal of radiology.
[20] L. Poll,et al. Imaging and quantifying skeletal involvement in Gaucher disease. , 2002, The British journal of radiology.
[21] C. Hollak,et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. , 2001, Blood cells, molecules & diseases.
[22] D. Häussinger,et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results , 2001, Skeletal Radiology.
[23] R. O'Donnell,et al. Pseudo-osteomyelitic crisis upon presentation of Gaucher disease , 2001, Skeletal Radiology.
[24] P. Kaplan,et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.
[25] G. Pastores,et al. Bone and joint complications related to Gaucher disease , 2000, Current rheumatology reports.
[26] P. Meikle,et al. Prevalence of lysosomal storage disorders. , 1999, JAMA.
[27] G. Hermann,et al. Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement , 1997, Skeletal Radiology.
[28] R. Longo,et al. Bone marrow relaxation times in Gaucher disease before and after enzyme replacement therapy , 1997, European Radiology.
[29] P. Colletti,et al. MR imaging of patients with type 1 Gaucher's disease: relationship between bone and visceral changes. , 1995, AJR. American journal of roentgenology.
[30] R. Mcpherson,et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. , 1993, American journal of human genetics.
[31] J. Dambrosia,et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. , 1992, Radiology.
[32] J. Dambrosia,et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.
[33] M. Clouse,et al. Gaucher disease: assessment with MR imaging. , 1986, Radiology.
[34] J. Scott,et al. Evaluation of Gaucher disease using magnetic resonance imaging. , 1986, The Journal of bone and joint surgery. American volume.
[35] R. Brady,et al. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. , 1966, The Journal of clinical investigation.
[36] M. Makin,et al. Aseptic osteomyelitis in Gaucher's disease. , 1965, Israel journal of medical sciences.